Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.45 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1180075 | 0.94 | KDM4E (0.62) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL29849556 | 0.88 | KDM4E (0.59) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL4779223 | 0.88 | KDM4E (0.59) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL7818523 | 0.84 | GPR84 (0.48) | KDM4EKCNH2GPR84L3MBTL1 | |
| SCHEMBL7809325 | 0.84 | KDM4E (0.44) | KDM4EMEN1KMT2AKCNH2HDAC6 | |
| SCHEMBL7237460 | 0.82 | KDM4E (0.61) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL1246531 | 0.81 | KDM4E (0.56) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL11044035 | 0.81 | KDM4E (0.56) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL12885024 | 0.80 | KDM4E (0.69) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL6245912 | 0.80 | MRGPRX4 (0.52) | KDM4EMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1198822-C | Angiogenesis inhibiting thiadiazolyl pyridazine derivatives | JANSSEN PHARMACEUTICA B V (BE) | 2005-04-27 | — | — | CN | disclosed |
| US-6649623-B1 | Administering tetrahydropiperidine derivative; antidiabetic agents; hyperlipemia treatment; hypotensive agents | SHIONOGI & CO., LTD. (JP) | 2003-11-18 | — | — | US | disclosed |
| US-6602873-B2 | Angiogenesis inhibiting thiadiazolyl pyridazine derivatives | JANSSEN PHARAMACEUTICA, N.V. (BE) | 2003-08-05 | — | — | US | disclosed |
| EP-0991649-B1 | ANGIOGENESIS INHIBITING THIADIAZOLYL PYRIDAZINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2003-03-26 | — | — | EP | disclosed |
| US-20010046999-A1 | Angiogenesis inhibiting thiadiazolyl pyridazine derivatives | STOKBROEKX RAYMOND ANTOINE (BE) | 2001-11-29 | — | — | US | disclosed |
| EP-1151993-A1 | CYCLIC AMINE DERIVATIVES AND USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2001-11-07 | — | — | EP | disclosed |
| US-6265407-B1 | WOUND HEALING AGENTS; ANTITUMOR AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-07-24 | — | — | US | disclosed |
| CN-1261364-A | Angiogenesis inhibiting thiadiazolyl pyridazine derivatives | JANSSEN PHARMACEUTICA B V (BE) | 2000-07-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010046999-A1 | Angiogenesis inhibiting thiadiazolyl pyridazine derivatives | KDR, TEK, TIE1 | KDM4E 1502/4885SMN1; SMN2 3827/4885ALDH1A1 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.